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hysician Judgment in Cardiology
he Art of Medicine Lives On*
ri Ben-Yehuda, MD, FACC
an Diego, California
he randomized clinical trial has become the apotheosis of
ur endeavor to determine the efficacy of different therapies.
robably no other field in medicine has embraced clinical
rials as has cardiovascular medicine, the home of the
egatrial. The overall success of the modern clinical trial
as led to a great emphasis on what has been termed
vidence-based medicine. Certainly, when it comes to
hether a particular medication has benefit, the comparison
ith a placebo can give scientifically reliable evidence
although even here whether the benefit extends to all can
e obscured by broad inclusion criteria and the limitations
f subgroup analyses [1]).
Randomized clinical trial design has also been applied
o complex decisions in medicine, including the appro-
riate choice of invasive procedures. In cardiovascular
edicine there is now a rich history of such trials, and
hey have impacted our daily decision-making process for
myriad of cardiac conditions from revascularization
trategies to timing of valve replacement to implantation
f a cardioverter-defibrillator.
See page 948
Randomized clinical trials, whether of a pharmacologic or
mechanical intervention, are based on the assumption that
atients in the different arms being compared have similar
aseline characteristics. In the case of the comparison of
oronary artery bypass grafting (CABG) versus percutane-
us coronary intervention (PCI), the assumption is that
oth treatments would be of equal a priori appropriateness.
ut the physician as well as patient preference may include
host of factors beyond those included in clinical trial
riteria and that may have biologic significance. Some of
hese may simply reflect the overly simplistic assessment of
oronary anatomy inherent in clinical trial criteria compared
ith the individualized reading of angiograms, more fully
eflective of each patient’s unique anatomy. Moreover, our
ecisions are often guided by our overall experience and the
gestalt” of the patient’s suitability for the procedure. Is
here room, therefore, in this evidence-based era for indi-
idual physician and patient judgment? Are outcomes in-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thet
merican College of Cardiology.
From the Division of Cardiology, University of California, San Diego, California.orporating such judgment better than the reliance on
vidence-based clinical trial data?
Some insight into the possible role of physician (and
atient) judgment in the process of choosing between
evascularization procedures has been gained from the
ccompanying registries of trials such as the EAST (Emory
ngioplasty versus Surgery Trial) (2), BARI (Bypass An-
ioplasty Revascularization Investigation) (3), and the
WESOME (Veterans Affairs’ Angina With Extremely
erious Operative Mortality Evaluation) trial (4). In these
hree trials comparing PCI and CABG, patients who had
imilar inclusion criteria but were not randomized in the
linical trials were enrolled in the accompanying registries.
he randomized EAST study (2) showed equivalency
etween angioplasty and CABG in 3-year survival, myocar-
ial infarction, and major myocardial ischemia. Baseline
haracteristics seemed to be similar between the patients in
he registry and the randomized trial, yet patients in the
egistry (5) seemed to do somewhat better than patients
andomized in the trial, with 3-year survival being 96.4%
ersus 93.4%. It was suggested that physician judgment may
ave guided patients to better decisions in the registry. In
he BARI trial (3), of 4,039 patients with multivessel
oronary artery disease, only 1,829 consented to random-
zation. The remaining patients were followed in a registry
6). The main study showed overall equivalency between
ABG and angioplasty, but also showed that diabetic
atients had a significant survival advantage with CABG
5-year mortality of 19% vs. 35%). Interestingly, within the
egistry this striking advantage of CABG in diabetic pa-
ients was not apparent, with an all-cause mortality of 14.9%
or angioplasty versus 14.9% for CABG (6), although there
as some increase in risk with angioplasty after adjusting for
aseline differences (risk ratio for mortality of 1.29) (7).
In the difficult decision between PCI and CABG, not
nly physician judgment but also patient judgment plays an
mportant role. Both the BARI and the EAST registry
ublications emphasized physician judgment in the registry
esults. Although patients tend to choose PCI over CABG
ore often, the AWESOME registry also included a group
f patients who were deemed equally eligible for either PCI
r CABG but refused randomization. These patients (n 
27) constituted a patient-choice registry (8). They were
ompared with 1,650 patients in whom the physicians
hemselves did not agree on the appropriateness of random-
zation (physician-directed registry) as well as the 454
atients who consented to randomization. All 3 groups had
imilar survival, with a trend for best outcome in the
atient-choice PCI patients (8).
Although the aforementioned registries and their com-
arison with the randomized trials provided insights into
he role of physician and patient judgment, they are limited
y possible confounders and selection bias. Indeed there
ay be significant differences between patients who consento be randomized and those who do not. How can one test
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September 5, 2006:954–5 Editorial Commentor physician (and patient) judgment while maintaining the
andomization in a clinical trial? The answer to this seeming
on-sequitur is published in this issue of the Journal. Pereira
t al. (9) used a most ingenious method. Within the context
f the MASS II (Medicine, Angioplasty, or Surgery Study)
10), a randomized trial comparing medical, percutaneous,
nd surgical treatment of stable multivessel coronary artery
isease, they recorded the consensus preference of two
ardiology physicians before the patient’s randomization.
hey then examined the outcome in patients who happened
o be randomized to the treatment modality that the two
onsultant cardiologists preferred (concordant group) com-
ared with those randomized to a treatment modality that
iffered from the physicians’ choice (discordant group).
nterestingly, there was an increased event rate in the
iscordant group, with a higher incidence of patients re-
uiring revascularization for refractory angina. The main
ifference was explained by an increased event rate in the
atients who underwent PCI but were in the discordant
roup (i.e., their physicians would not have chosen PCI for
hose patients). Angiographic characteristics identified by
he physicians but not captured in the criteria for inclusion
n the trial were identified as significantly different between
he concordant and discordant group. The presence of
hree-vessel disease was a clear predictor of discordance, but
early half of concordant PCI patients also had three-vessel
isease, suggesting that more complex physician assessment
f PCI feasibility was involved.
The MASS II trial showed an advantage to the medical
herapy group when the entire randomized population is
xamined (10). Interestingly, in the concordant subgroup,
ll three modalities had a similar outcome, suggesting that
hysician judgment was helpful in correctly identifying the
ppropriate treatment modality, particularly those patients
ho should not have PCI.
The interesting report from the MASS II study is limited
y a relatively small overall sample size of 611 patients and
he lack of drug-eluting stents. The possible role of patient
udgment was not evaluated (conceivably patients could be
sked to report what their choice is before randomization as
ell). Still, this intriguing report is noteworthy both for its
emonstration of the importance of clinical judgment asell as for its unique and creative methodology. As we
ontinue to embrace evidence-based medicine as well as
valuate randomized clinical trials, the important lessons
rom this report of the MASS II study should also be kept
n mind. It is indeed reassuring that there is still a role for
he art of medicine.
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